# Lorlatinib Continuation Study

> **NCT05144997** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 76 (actual)

## Conditions studied

- Non-Small-Cell Lung Cancer
- NSCLC

## Interventions

- **DRUG:** Lorlatinib

## Key facts

- **NCT ID:** NCT05144997
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-28
- **Primary completion:** 2026-12-28
- **Final completion:** 2026-12-28
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05144997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05144997, "Lorlatinib Continuation Study". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05144997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*